Day One Biopharmaceuticals, Inc. (DAWN) Analyst Estimates Annual - Discounting Cash Flows
DAWN
Day One Biopharmaceuticals, Inc.
DAWN (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
Number of Analysts 2 5 7 8 8 7
Estimated Revenue
Low 453.5 389.3 297.6 195.3 148.5 119.6
Average 549.4 404.4 307.8 231 151.5 122.5
High 687.6 419.4 318 282.9 158.3 124.3
Estimated EBITDA
Low 303.1 260.2 198.9 130.5 99.22 79.91
Average 367.2 270.3 205.7 154.4 101.3 81.91
High 459.6 280.3 212.5 189.1 105.8 83.11
Estimated EBIT
Low 301.7 259 198 129.9 98.76 79.54
Average 365.5 269 204.8 153.7 100.8 81.53
High 457.5 279 211.5 188.2 105.3 82.72
Estimated Net Income
Low 102.8 34.43 -22.59 -162.7 -99.57 -79.33
Average 132.9 82.26 18.07 -54.48 -90.78 -69.08
High 176.4 177.1 65.58 0.889 -82 -65.33
Estimated SGA Expenses
Low 442.6 380 290.5 190.6 144.9 116.7
Average 536.3 394.7 300.4 225.5 147.9 119.6
High 671.2 409.4 310.3 276.2 154.5 121.4
Estimated EPS
Low 1.1 0.368 -0.241 -1.74 -1.06 -0.847
Average 1.42 0.801 0.13 -0.541 -1 -0.728
High 1.88 1.89 0.7 0.009 -0.876 -0.698
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program